These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 30392161)

  • 1. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease.
    Cobo-Ibáñez T; López-Longo FJ; Joven B; Carreira PE; Muñoz-Fernández S; Maldonado-Romero V; Larena-Grijalba C; Cubas IL; Muriel ET; Mateos CB; de la Peña Lefebvre PG; Gomez-Gomez A; Nogal LB; Pérez A; Almodovar R; Lojo L; Ruiz-Gutiérrez L; López-Robledillo JC; García de Yébenes MJ; Nuño-Nuño L
    Clin Rheumatol; 2019 Mar; 38(3):803-815. PubMed ID: 30392161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome.
    Zamora AC; Hoskote SS; Abascal-Bolado B; White D; Cox CW; Ryu JH; Moua T
    Respir Med; 2016 Sep; 118():39-45. PubMed ID: 27578469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
    Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.
    Johnson C; Pinal-Fernandez I; Parikh R; Paik J; Albayda J; Mammen AL; Christopher-Stine L; Danoff S
    Lung; 2016 Oct; 194(5):733-7. PubMed ID: 27166633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.
    Trallero-Araguás E; Grau-Junyent JM; Labirua-Iturburu A; García-Hernández FJ; Monteagudo-Jiménez M; Fraile-Rodriguez G; Les-Bujanda I; Rodriguez-Carballeira M; Sáez-Comet L; Selva-O'Callaghan A;
    Semin Arthritis Rheum; 2016 Oct; 46(2):225-231. PubMed ID: 27139168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary manifestations of polymyositis/dermatomyositis.
    Hallowell RW; Ascherman DP; Danoff SK
    Semin Respir Crit Care Med; 2014 Apr; 35(2):239-48. PubMed ID: 24668538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry.
    Nuño-Nuño L; Joven BE; Carreira PE; Maldonado-Romero V; Larena-Grijalba C; Llorente Cubas I; Tomero E; Barbadillo-Mateos MC; García de la Peña Lefebvre P; Ruiz-Gutiérrez L; López-Robledillo JC; Moruno-Cruz H; Pérez A; Cobo-Ibáñez T; Almodóvar R; Lojo L; García de Yébenes MJ; López-Longo FJ
    Int J Rheum Dis; 2019 Aug; 22(8):1393-1401. PubMed ID: 30968571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
    Hozumi H; Fujisawa T; Nakashima R; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
    Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
    BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Interstitial Lung Disease-Gender-Age-Physiology Index Can Predict the Prognosis in Surgically Resected Patients with Interstitial Lung Disease and Concomitant Lung Cancer.
    Ueno F; Kitaguchi Y; Shiina T; Asaka S; Yasuo M; Wada Y; Kinjo T; Yoshizawa A; Hanaoka M
    Respiration; 2020; 99(1):9-18. PubMed ID: 31554007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and immunological characteristics of 88 cases of overlap myositis].
    Xiao YS; Zhu FY; Luo L; Xing XY; Li YH; Zhang XW; Shen DH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1088-1093. PubMed ID: 34916687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies.
    Shao C; Xia N; Zhen Y; Zhang X; Yan N; Guo Q
    Front Immunol; 2024; 15():1404828. PubMed ID: 38745647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raynaud's phenomenon and anti-nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositis.
    Park EH; Hwang WC; Lee Y; Lee EY; Lee EB; Song YW; Park JK
    Int J Rheum Dis; 2019 Mar; 22(3):507-515. PubMed ID: 30548402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.
    Nuño-Nuño L; Joven BE; Carreira PE; Maldonado-Romero V; Larena-Grijalba C; Cubas IL; Tomero EG; Barbadillo-Mateos MC; De la Peña Lefebvre PG; Ruiz-Gutiérrez L; López-Robledillo JC; Moruno-Cruz H; Pérez A; Cobo-Ibáñez T; Almodóvar González R; Lojo L; García De Yébenes MJ; López-Longo FJ
    Rheumatol Int; 2017 Nov; 37(11):1853-1861. PubMed ID: 28866745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.
    Bai Z; Shen G; Dong L
    Int J Rheum Dis; 2021 Jun; 24(6):815-827. PubMed ID: 34028988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
    Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
    Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic inflammatory myopathies and the lung.
    Lega JC; Reynaud Q; Belot A; Fabien N; Durieu I; Cottin V
    Eur Respir Rev; 2015 Jun; 24(136):216-38. PubMed ID: 26028634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort.
    Chua F; Higton AM; Colebatch AN; O'Reilly K; Grubnic S; Vlahos I; Edwards CJ; Kiely PD
    Rheumatology (Oxford); 2012 Oct; 51(10):1870-6. PubMed ID: 22763991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.